Skip to main content
Premium Trial:

Request an Annual Quote

Sciex and Pressure Biosciences Ink Comarketing Deal

NEW YORK (GenomeWeb) – Sciex and Pressure Biosciences have signed an exclusive comarketing agreement, the companies said today.

Under the deal, PBI will promote its pressure cycling technology (PCT) sample prep systems with Sciex's Swath-based proteomics workflows as well as its TripleTOF, QTRAP, and triple quadrupole mass spec systems.

PBI's PCT systems use controlled cycles of pressure to break down samples, allowing for improved extraction of molecules such as proteins. In the case of proteomic workflows, this can improve the depth and reproducibility of mass spec coverage.

Initial work on combining PCT with Swath mass spec was done by Ruedi Aebersold and Tiannan Guo at the Swiss Federal Institute of Technology and the University of Zurich. According to the researchers, the method, which they termed PCT-Swath, allows for Swath-based proteome analyses in 12 hours from the start of processing tissue, considerably shorter than conventional workflows, which can take days.

"By addressing the significant challenges inherent in complex sample preparation to reproducibly analyze thousands of proteins in hundreds of samples, PCT-Swath accelerates proteomics research in biologically and clinically relevant contexts," Aebersold said in a statement. "This should increase the chance for biomarker discovery, potentially leading to significant improvements in healthcare, including personalized medicine."

"The net result [of the PCT-Swath approach] is more comprehensive protein quantitation for complex samples, increased productivity, and higher quality results," said Mark Cafazzo, director of academic and clinical research business at Sciex, in the statement.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.